Ripasudil
As of the edition of 20 October 2026, Ripasudil is a small molecule: marketed, first approved in 2014 (JP); acts on ROCK1 and ROCK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Glanatec
- First approved
- 26 September 2014 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Kowa
- Registered trials
- 10, 0 stopped early
- Disease areas
- Eye; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| Phase 2 | 3 | 1 | 0 | 0 |
| Phase 3 | 6 | 3 | 3 | 0 |
| All trials | 10 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Kowa | Applicant | 2014 to now |